Table 3. MDM2 and p14ARF polymorphisms and risk of SGC.
| Genotype | Controls | Cases | P a | Adjusted ORb (95% CI) | ||||
| (No. = 511) | (No. = 156) | |||||||
| No. | (%) | No. | (%) | |||||
| MDM2-rs2279744 | ||||||||
| TG/GG | 341 | (66.7) | 89 | (57.0) | 0.027 | 1.0 | ||
| TT | 170 | (33.3) | 67 | (43.0) | 1.5 (1.1–2.2) | |||
| MDM2-rs937283 | ||||||||
| AG/GG | 338 | (66.1) | 97 | (62.2) | 0.363 | 1.0 | ||
| AA | 173 | (33.9) | 59 | (37.8) | 1.2 (0.8–1.8) | |||
| p14ARF-rs3731217 | ||||||||
| TT | 388 | (75.9) | 109 | (69.9) | 0.129 | 1.0 | ||
| TG/GG | 123 | (24.1) | 47 | (30.1) | 1.3 (0.9–2.0) | |||
| p14ARF-rs3088440 | ||||||||
| GA/AA | 109 | (21.3) | 31 | (19.9) | 0.695 | 1.0 | ||
| GG | 402 | (78.7) | 125 | (80.1) | 1.2 (0.7–1.9) | |||
a
Chi-square test, compared to controls.
b
Adjusted for age, sex, race/ethnicity, and radiation exposure.